Mitchell Psotka, MD
Cardiovascular Disease · Falls Church, VANPI 1942525381
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $28,545 of the $34,661 with a category attached, or 82.4%. Amgen accounts for 83.6% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2020 at $23,500 and has fallen 99.9% since, to $20 in 2024. Among cardiovascular disease clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 44 payments — averaging $787.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$29K
- Boehringer Ingelheim$4K
- Abbott$664
- United Therapeutics Corporation$311
- Abiomed$162
- Actelion Pharmaceuticals US, Inc.$140
- plus $220 from 5 others
Across 30 payments — averaging $7047.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$91K
- Janssen Research & Development, LLC$85K
- Abbott$27K
- United Therapeutics Corporation$8K
What the payments were for
- Consulting fees$28,54582%
- Speaking & faculty fees$4,18112%
- Travel & lodging$3981%
- Food & beverage$1,5384%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 8 | $28,982 |
| Boehringer Ingelheim | 1 | $4,181 |
| Abbott | 10 | $664 |
| United Therapeutics Corporation | 13 | $311 |
| Abiomed | 3 | $162 |
| Actelion Pharmaceuticals US, Inc. | 2 | $140 |
| Merck | 1 | $103 |
| Bayer | 2 | $39 |
| Gilead | 2 | $36 |
| Medtronic | 1 | $23 |
| Pfizer | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,661 in reported general payments places this provider in the 90th percentile of 548 cardiovascular disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 23 | $509,609 |
| JardianceEmpagliflozin | 45 | $66,936 |
| EntrestoSacubitril/Valsartan | 39 | $49,102 |
| FarxigaDapagliflozin Propanediol | 27 | $31,020 |
| Eplerenone | 44 | $2,392 |
| Tadalafil | 25 | $1,912 |
| Metoprolol Succinate | 48 | $986 |
| Torsemide | 23 | $535 |
| Spironolactone | 42 | $302 |
| MethotrexateMethotrexate Sodium | 18 | $205 |
| Carvedilol | 31 | $198 |
| Furosemide | 24 | $113 |
| Losartan Potassium | 18 | $110 |
| Atorvastatin Calcium | 12 | $54 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax | $20 | $509,60923 claims |
| Boehringer IngelheimJardiance | $4,181 | $66,93645 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 548 cardiovascular disease providers in Virginia.
Other cardiovascular disease in Falls Church
- Alexander TruesdellFalls Church$167K
- Christopher OconnorFalls Church$161K
- Joseph KreppFalls Church$74K
- Behnam TehraniFalls Church$58K
- Tariq HaddadFalls Church$18K
- Leonard IlkhanoffFalls Church$14K
- Shashank SinhaFalls Church$12K
- George VetrovecRichmond$2.3M
- Hamid TaheriManassas$501K
- Cyrus HadadiNorfolk$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.